Alves, R.; Gonçalves, A.C.; Jorge, J.; Almeida, A.M.; Sarmento-Ribeiro, A.B.
Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines 2022, 10, 1158.
https://doi.org/10.3390/biomedicines10051158
AMA Style
Alves R, Gonçalves AC, Jorge J, Almeida AM, Sarmento-Ribeiro AB.
Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines. 2022; 10(5):1158.
https://doi.org/10.3390/biomedicines10051158
Chicago/Turabian Style
Alves, Raquel, Ana Cristina Gonçalves, Joana Jorge, António M. Almeida, and Ana Bela Sarmento-Ribeiro.
2022. "Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia" Biomedicines 10, no. 5: 1158.
https://doi.org/10.3390/biomedicines10051158
APA Style
Alves, R., Gonçalves, A. C., Jorge, J., Almeida, A. M., & Sarmento-Ribeiro, A. B.
(2022). Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines, 10(5), 1158.
https://doi.org/10.3390/biomedicines10051158